101
|
Mayer S, Hirschfeld M, Jäger M, Stickeler E, Gitsch G. Expressionmuster und Splicingverhalten der Rezeptortyrosinkinase RON in Ovarialkarzinomen. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
102
|
Luft D, Lemmen S, Geipel U, Meerbach D, Scheithauer S, Jäger M, Eckmann C, Dettenkofer M. [Infection control in the operating room: preventive measures and isolation precautions in cases of multidrug resistant pathogens]. Zentralbl Chir 2011; 137:284-92. [PMID: 21667444 DOI: 10.1055/s-0031-1271525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND Providing surgical treatment for patients colonised or infected with multidrug resistant organisms (MDROs) is daily routine in German hospitals. However, there is uncertainty about the application of adequate infection control measures in the OR. One of the reasons is that specific guidelines are not available. MATERIAL AND METHODS We evaluated current practice in surgical departments of selected German university medical centres using a questionnaire. In addition, centres were asked to provide in-house standard operating procedures (SOP), if available. RESULTS Nineteen questionnaires from 19 departments within 4 centres and 5 in-house SOPs were ana-lysed. The results showed a broad spectrum of applied infection control measures. Wide variations existed both within centres and within departments of the same centre regardless of existing in-house standards. CONCLUSIONS Guidelines addressing perioperative infection control measures for patients harbouring MDROs should be developed with a focus on practicability to reduce both transmission of MDROs and unreasonable measures. Implementation of existing SOPs can be a target for optimisation.
Collapse
|
103
|
Ruf P, Jäger M, Foerster B, Martinius H, Seimetz D, Lindhofer H. Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2575] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
104
|
Jäger M, Kienle A. Non-invasive determination of the absorption coefficient of the brain from time-resolved reflectance using a neural network. Phys Med Biol 2011; 56:N139-44. [DOI: 10.1088/0031-9155/56/11/n02] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
105
|
Jäger M, Frasch K, Becker T. [Erik Essen-Möller and the roots of multiaxial classification in psychiatry]. FORTSCHRITTE DER NEUROLOGIE-PSYCHIATRIE 2011; 79:277-82. [PMID: 21544760 DOI: 10.1055/s-0031-1273198] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Against the background of the preparation of ICD-11 and DSM-V, the historical roots of a multiaxial diagnostic assessment in psychiatry are reviewed. The principles of such an approach are traced back to the Swedish psychiatrist Erik Essen-Möller who had proposed a distinction between aetiological and descriptive aspects in the classification of mental disorders. Furthermore, he suggested to break down the descriptive classification into the cross-sectional psychopathological picture and the clinical course. Nowadays, a multiaxial assessment is used in diagnostic systems such as DSM-IV. However, these current concepts differ considerably from Essen-Möller's suggestions. A return to the original approach of multiaxial diagnostic assessment comprising the axes "syndromes", "course types" and "aetiology" would be in line with current neurobiological findings and may provide a bridge between the traditional categorical diagnostic approach and dimensional models.
Collapse
|
106
|
Drescher W, Pufe T, Smeets R, Eisenhart-Rothe RV, Jäger M, Tingart M. Hüftkopfnekrose – Diagnostik und Differenzialtherapie. ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE 2011; 149:231-40; quiz 241-2. [DOI: 10.1055/s-0030-1270984] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
107
|
Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand 2011; 123:228-38. [PMID: 21029053 DOI: 10.1111/j.1600-0447.2010.01608.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To examine depressive symptoms, their course during treatment, and influence on outcome. METHOD Weekly Calgary Depression Scale for Schizophrenia ratings were performed in 249 inpatients with schizophrenia. Early response was defined as a 20% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia from admission to week 2, response as a 50% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) from admission to discharge and remission according to the consensus criteria. RESULTS Thirty six per cent of the patients were depressed at admission, with 23% of them still being depressed at discharge. Depressed patients scored significantly higher on the PANSS negative and general psychopathology subscore, featured more impairments in subjective well-being (P < 0.0001) and functioning (P < 0.0001). They suffered from more suicidality (P = 0.0021), and had greater insight into their illness (P = 0.0105). No significant differences were found regarding early response, response, and remission. CONCLUSION Patients with depressive symptoms should be monitored closely, given the burden of negative symptoms, their impairments in well-being and functioning and the threat of suicidality.
Collapse
|
108
|
Schennach-Wolff R, Möller HJ, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. PHARMACOPSYCHIATRY 2010; 43:245-51. [PMID: 20927697 DOI: 10.1055/s-0030-1262788] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BACKGROUND The aim of this paper is to apply the proposed consensus remission criteria to an acutely ill inpatient sample at admission and evaluate their adaptability in this patient population and pharmaceutical trials. METHODS The Remission in Schizophrenia Working Group's consensus criteria were applied to 272 acutely ill schizophrenia patients. Patients were examined using the PANSS, HAMD, UKU and SWN-K total scales at admission as well as the GAF, SOFAS and the Strauss-Carpenter Prognostic Scale. Sociodemographic and clinical baseline variables were assessed using a standardized documentation system. RESULTS 33 patients (12%) fulfilled the symptom severity component of the proposed remission criteria already at baseline. Almost no significant differences were found when comparing patients with achieved and failed symptom severity component that would explain the hospitalization of the patients with achieved criteria despite their apparently mild psychopathological symptoms. The only explainable difference was that patients with an achieved symptom severity component had received significantly more antipsychotics and had suffered from significantly more life events before admission. CONCLUSION The present results raise the question whether the symptom severity threshold is adequate to identify patients in remission when applied in clinical trials.
Collapse
|
109
|
Zilkens C, Jäger M, Bittersohl B, Kim YJ, Millis M, Krauspe R. Epiphysenlösung. DER ORTHOPADE 2010; 39:1009-21. [DOI: 10.1007/s00132-010-1659-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
110
|
Jäger M, Bittersohl B, Zilkens C, Herten M, Krauspe R. [Regeneration of osteochondral defects in the knee]. ZEITSCHRIFT FUR ORTHOPADIE UND UNFALLCHIRURGIE 2010; 149:37-44. [PMID: 20645254 DOI: 10.1055/s-0030-1250059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The application of autologous cells is a standard procedure for the treatment of chondral lesions of the knee. Here, the most frequently used cells are differentiated chondrocytes (autologous chondrocyte implantation, ACI; matrix-induced autologous chondrocyte implantation, MACI). The enzymatic digestion of cartilage tissue by collagenase and isolation of chondrocytes followed by in vitro cultivation are associated with cellular de- and transdifferentiation. To prevent these effects some authors recommend 3D-cultures and culture medium supplementation of defined growth factors and cytokines. Another aim is the reduction of donor site morbidity. Therefore, different progenitor cell types were tested towards their potential for osteochondral regeneration. In particular, MSC derived from bone marrow include several advantages for the treatment of osteochondral defects such as unproblematic sampling, cultivation techniques, and a relatively high degree of biological safety. This review summarises the basic cellular principles as well as clinical results of cell therapeutics for the regeneration of osteochondral defects in the knee.
Collapse
|
111
|
Jäger M, Haack S, Becker T, Frasch K. Schizoaffective disorder--an ongoing challenge for psychiatric nosology. Eur Psychiatry 2010; 26:159-65. [PMID: 20646917 DOI: 10.1016/j.eurpsy.2010.03.010] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2009] [Revised: 02/12/2010] [Accepted: 03/04/2010] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE Schizoaffective disorder is a common diagnosis in mental health services. The present article aims to provide an overview of diagnostic reliability, symptomatology, outcome, neurobiology and treatment of schizoaffective disorder. METHOD Literature was identified by searches in "Medline" and "Cochrane Library". RESULTS The diagnosis of schizoaffective disorder has a low reliability. There are marked differences between the current diagnostic systems. With respect to psychopathological symptoms, no clear boundaries were found between schizophrenia, schizoaffective disorder and affective disorders. Common neurobiological factors were found across the traditional diagnostic categories. Schizoaffective disorder according to ICD-10 criteria, but not to DSM-IV criteria, shows a more favorable outcome than schizophrenia. With regard to treatment, only a small and heterogeneous database exists. CONCLUSION Due to the low reliability and questionable validity there is a substantial need for revision and unification of the current diagnostic concepts of schizoaffective disorder. If future diagnostic systems return to Kraepelin's dichotomous classification of non-organic psychosis or adopt a dimensional diagnostic approach, schizoaffective disorder will disappear from the psychiatric nomenclature. A nosological model with multiple diagnostic entities, however, would be compatible with retaining the diagnostic category of schizoaffective disorder.
Collapse
|
112
|
Pietzner K, Linke RG, Jäger M, Lindhofer H, Friccius-Quecke H, Chen F, Braicu EI, Oskay-Özcelik G, Sehouli J. Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps155] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
113
|
Jäger M, Schoberth A, Hennig M, Burges A, Heiss M, Wimberger P, Schmalfeldt B, Lindhofer H. The trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
114
|
Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Acta Psychiatr Scand 2010; 121:359-70. [PMID: 19878135 DOI: 10.1111/j.1600-0447.2009.01484.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. METHOD Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorders. Response was defined as an initial 20% PANSS total score reduction at discharge, remission was defined according to the proposed consensus criteria by the Remission in Schizophrenia Working Group. RESULTS Suicidal patients (22%) scored significantly higher on the PANSS negative subscore, PANSS insight item and HAMD total score at admission and at discharge. They developed significantly more side effects. No differences were found concerning response and remission between the two patient subgroups. CONCLUSION Despite receiving significantly more antidepressants the suicidal patients suffered from significantly more depressive symptoms up to discharge, yet without differing regarding response and remission.
Collapse
|
115
|
Jäger M, Riedel M, Obermeier M, Schennach-Wolff R, Seemüller F, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rüther E, Klingberg S, Gastpar M, Bottlender R, Möller HJ. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophr Res 2010; 118:183-8. [PMID: 20181461 DOI: 10.1016/j.schres.2010.02.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2009] [Revised: 01/29/2010] [Accepted: 02/02/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions. METHODS Two hundred and eighty inpatients with schizophrenia (DSM-IV criteria) were assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge. RESULTS The mean duration of inpatient treatment was 54.8 days. Of the total sample, 78.5% achieved the criteria for response and 44.6% those for remission. Mean PANSS total scores decreased from 72.4 at admission to 52.5 at discharge (p<0.001). A reduction in PANSS total scores was found from visit to visit, up to week 8. The most pronounced decline was observed within the first two weeks of treatment. CONCLUSION Response rates were comparable to those found in efficacy studies, and remission rates were slightly higher. This may be explained by differences in the selection and the treatment of patients. Nevertheless, the findings might indicate that a complex naturalistic treatment approach is beneficial in terms of effectiveness.
Collapse
|
116
|
Handel S, Jäger M. [Emotional instability and suicidal behavior as a consequence of transsexualism]. DER NERVENARZT 2010; 81:335-338. [PMID: 20111853 DOI: 10.1007/s00115-009-2915-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
This contribution describes a case that led to hospitalization in our psychiatric clinic due to emotional instability and suicidal behavior resulting from a gender identity disorder (female to male transsexualism). During inpatient treatment that lasted for almost 4 months, considerable improvement of the patient's emotional instability and suicidal behavior could be achieved. Treatment success was maintained up to follow-up (18 months after discharge). The syndrome-oriented pharmacotherapy with quetiapine and valproate which had been administered as off-label medication to stabilize the patient's mood could be considered the effective factor. A few months after release from inpatient care, cross-gender hormone therapy was initiated accompanied by outpatient psychotherapy.
Collapse
|
117
|
Jäger M, Hernigou P, Zilkens C, Herten M, Fischer J, Krauspe R. Zelltherapie bei Knochenheilungsstörungen. DER ORTHOPADE 2010; 39:449-62; quiz 463. [DOI: 10.1007/s00132-009-1583-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
118
|
Schennach-Wolff R, Mayr A, Seemüller F, Jäger M, Moeller HJ, Riedel M. PW01-192 - Development of a valid early improvement threshold to predict response and remission in FES. Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)71599-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
119
|
Jäger M, Becker T, Weinmann S, Frasch K. Treatment of schizoaffective disorder - a challenge for evidence-based psychiatry. Acta Psychiatr Scand 2010; 121:22-32. [PMID: 19570108 DOI: 10.1111/j.1600-0447.2009.01424.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Schizoaffective disorder is a common diagnosis in mental health services. The aim of the present article was to review treatment studies for schizoaffective disorder and draw conclusions for clinical decision making. METHOD We searched MEDLINE and Cochrane Library for relevant clinical trials and review articles up to the year 2008. RESULTS Thirty-three studies using standardized diagnostic criteria, 14 of which were randomized controlled trials, could be identified. The comparability of studies is limited by the use of different diagnostic criteria. The studies reviewed do not permit consistent recommendations as to whether schizoaffective disorder should be treated primarily with antipsychotics, mood stabilizers or combinations of these drugs. The relevance of diverse subtypes of schizoaffective disorder for treatment recommendations is unclear. CONCLUSION The pertinent empirical database is small and heterogeneous. The lack of conclusive recommendations is related to issues of nosological status, plurality of diagnostic criteria and validity of the concept of schizoaffective disorder.
Collapse
|
120
|
Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2009; 87:191-6. [PMID: 19924124 DOI: 10.1038/clpt.2009.206] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We aimed to assess the effect of coadministration and withdrawal of a potent cytochrome P450 3A (CYP3A) inhibitor (ritonavir) and a potent CYP3A inducer (St John's wort) on CYP3A enzyme activity in an open, fixed-sequence study design. We investigated the pharmacokinetics of midazolam: (i) at baseline, (ii) after a single dose of either St John's wort or ritonavir (each n = 6), (iii) after 14 days of coadministration of ritonavir (300 mg b.i.d.) and St John's wort (300 mg t.i.d.), and (iv) at 2 days after cessation of both St John's wort and ritonavir. Combined administration of inducer and inhibitor resulted in a predominance of enzyme inhibition: coadministration of St John's wort and ritonavir with intravenous administration of midazolam resulted in an increase in the area under the plasma concentration-time curve (AUC)(0-8 h) of midazolam to 180% of baseline value, whereas with orally administered midazolam, the AUC(0-6 h) increased to 412% of baseline value (P < 0.05 for each). After cessation of the coadministered drugs, the AUC(0-6 h) of orally administered midazolam decreased to 6% of the level observed during combined administration, and the AUC(0-8 h) of intravenously administered midazolam decreased to 33% of the values observed during combined administration (P < 0.001 for each). Induction may be unmasked after the withdrawal of a combination of a potent CYP3A inhibitor and a potent CYP3A inducer, leading to substantial drops in drug exposure of CYP3A substrates. This may require substantial dose adjustments, particularly of orally administered drugs.
Collapse
|
121
|
Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jäger M. 1312 Catumaxomab therapy eliminates putative CD133+ EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70485-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
122
|
Schennach-Wolff R, Zill P, Jäger M, Seemüller F, Obermeier M, Bondy B, Möller HJ, Riedel M. Outcome of suicidal patients with schizophrenia and the possible genetic association: results from a naturalistic study. PHARMACOPSYCHIATRY 2009. [DOI: 10.1055/s-0029-1240215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
123
|
Jäger M, Schoberth A, Theissen B, Hess J, Friccius H, Lindhofer H. 1313 Catumaxomab treatment reduces VEGF protein levels within malignant ascites: data from a pivotal phase II/III study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70486-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
124
|
Schennach-Wolff R, Jäger M, Mayr A, Seemüller F, Möller HJ, Riedel M. Depressive symptoms and their influence and predictive validity on treatment outcome in patients with first-episode schizophrenia. PHARMACOPSYCHIATRY 2009. [DOI: 10.1055/s-0029-1240214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
125
|
Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jäger M. Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3014 Background: Putative cancer stems cells (CSCs) are defined as “tumor-initiating cells” that have the capacity to self-renew and to give rise to the variety of differentiated cells found in the malignancy. The CD133 membrane glycoprotein represents a CSC marker that has been previously demonstrated to be capable of identifying a cancer-initiating subpopulation in brain tumors, melanoma, and EpCAM+ solid tumors. The trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab efficiently eliminates tumor cells from the peritoneal fluid of malignant ascites (MA) patients as demonstrated in a pivotal phase II/III trial (Parsons et al., ASCO 2008). Here we report on the presence of CD133+/EpCAM+ putative CSCs in MA and, more importantly, on the elimination of this cell population from the peritoneal fluid of MA patients by means of catumaxomab therapy. Methods: 18 CTX-refractory patients with MA caused by a variety of primary carcinoma diseases (i.e., ovarian, pancreas, and gastric cancer) were analyzed for the presence CD133+/EpCAM+ cells in peritoneal fluids by means of CD133+/EpCAM+ double staining on cytospin preparations. Analyses were performed before, 2 days after the first, and 1 day after the last catumaxomab infusion, respectively. Double-stained cytospin preparations were evaluated with a computerized image analysis system. Results: Before therapeutic intervention, CD133+/EpCAM+ cells were detected in the peritoneal fluids of 14 from 18 patients suffering from MA. After the 1st infusion of catumaxomab (10μg), 9 of these 14 patients showed complete elimination of the CD133+/EpCAM+ cells. After 4 i.p. catumaxomab infusions (10μg day 0, 20μg day 3, 50μg day 7 and 150μg day 10) the CD133+/EpCAM+ cells were completely eliminated from the peritoneal fluids of all 14 MA patients. Conclusions: In a preliminary monitoring study, putative CSCs (CD133+/EpCAM+) were present in peritoneal fluids of 78 % of analyzed MA patients with different underlying primary tumor entities. Catumaxomab efficiently destroyed CD133+/EpCAM+ cells within peritoneal fluids of MA patients. Consequently, catumaxomab-based therapeutic measures may offer an additional treatment opportunity to eliminate CSCs in EpCAM+ malignancies. [Table: see text]
Collapse
|